Cyclic nucleotide phosphodiesterases and vascular smooth muscle

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 403-427

  Polson, James B ^a   Strada, Samuel J ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

asthma; cyclic nucleotide metabolism; PDE isozymes and inhibitors; pulmonary hypertension; vascular disease

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 1,3 DIHYDRO 5 (1,4,5,6 TETRAHYDRO 6 OXO 3 PYRIDAZINYL) 2H INDOL 2 ONE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; AMRINONE; CILOSTAMIDE; CILOSTAZOL; CIPROSTENE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPYRIDAMOLE; ENOXIMONE; IMAZODAN; INDOLIDAN; ISOENZYME; ISOMAZOLE; LY 186232; LY 195114; LY 197055; LY 197096; LY 198419; PHOSPHODIESTERASE INHIBITOR; PIROXIMONE; ROLIPRAM; SIGUAZODAN; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ARTERY OCCLUSION; CARDIOVASCULAR DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0029942933     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.36.040196.002155     Document Type: Review

References (90)

1. Chasin M, Harris DN. 1976. Inhibitors and activators of cyclic nucleotide phosphodiesterase. Adv. Cycl Nucl. Res. 7: 225-64
2. Sheppard H, Wiggan G, Tsien WH. 1972. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv. Cycl. Nucl Res. 1:103-12
3. Beavo JA, Conti M, Heaslip RJ. 1994. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:399-405
4. Lugnier C, Schoeffter P, Le Bee A, Strouthou E, Stoclet JC. 1986. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35:1743-51
5. Hidaka H, Endo T. 1984. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-basic and potential clinical applications. Adv. Cycl. Nucleotide Protein Phosphorylation. Res 16.245-76
6. Ivorra MD, Le Bec A, Lugnier C. 1992. Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle. J. Cardiovasc. Pharmacol. 19:532-40
7. Ahn HS, Crim W, Pitts B, Sybertz EJ. 1992. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Adv. Second Messenger Phosphoprotein Res. 25:271-88
8. Saeki T, Saito I. 1993. Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem. Pharmacol. 46:833-39
9. Souness JE, Brazdil R, Diocee BK, Jordan R. 1989. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22.948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br. J. Pharmacol. 98:725-34
10. Pagani ED, Buchholz RA, Silver PJ. 1992. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. Basic Res. Cardiol. 87(Suppl. 1):73-86
11. Silver PJ, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB. 1988. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 150:85-94
12. Hagiwara M, Endo T, Hidaka H. 1984. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 33:453-57
13. Ann HS, Crim W, Romano M, Sybertz E, Pitts B. 1989. Effects of selective inhibitors of cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 38:3331-39
14. Keravis TM, Wells JN, Hardman JG. 1980. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Biochim. Biophys. Acta 613: 116-29
15. Wells JN, Wu YJ, Baird CI, Hardman JG. 1975. Phosphodiesterases from porcine coronary arteries: inhibition of separated forms by xanthines, papaverine, and cyclic nucleotides. Mol. Pharmacol. 11:775-83
16. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. 1986. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem. Pharmacol. 35:787-800
17. Komas N, Lugnier C, Andriantsitohaina R, Stoclet J-C. 1991. Characterization of cyclic nucleotide phosphodiesterases from rat mesenteric artery. Eur. J. Pharmacol. 208:85-87
18. Ahn HS, Foster M, Cable M, Pitts BJR, Sybertz EJ. 1991. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv. Exp. Med. Biol. 308:191-97
19. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H 1994. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266:L536-43
20. Weishaar RE, Kobylarz-Singer DC, Keiser J, Haleen SJ, Major TC, Rapundalo S, et al. 1990. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor. Hypertension 15:528-40
21. Saitoh Y, Hardman JG, Wells JN. 1985. Differences in the association of calmodulin with cyclic nucleotide phosphodiesterase in relaxed and contracted arterial strips. Biochemistry 24:1613-18
22. 2+-calmodulin-sensitive phosphodiesterase activity in porcine coronary artery. Biochem. Pharmacol. 36:1819-24
23. m) cyclic adenosine monophosphate phosphodiesterase. Am. J. Cardiol. 63:2A-8A
24. Komas N, Lugnier C, Stoclet J-C. 1991. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104:495-503
25. Lugnier C, Komas N. 1993. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 14(Suppl. 1): 141-48
26. Rascon A, Lindgren S, Stavenow L, Belfrage P, Andersson K-E, et al. 1992. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim. Bioiphys. Acta 1134:149-56
27. Lindgren S, Rascon A, Andersson K-E, Manganiello V, Degerman E. 1991. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem. Pharmacol. 42: 545-52
28. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, et al. 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95: 1528-38
29. Prigent AF, Fougier S, Nemoz G, Anker G, Pacheco H, et al. 1988. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Biochem. Pharmacol. 37:3671-81
30. Frodsham G, Jones RB. 1992. Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle. Eur. J. Pharmacol. 211:383-91
31. Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT, Silver PJ. 1989. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J. Pharmacol. Exp. Ther. 249:394-400
32. Hidaka H, Tanaka T, Itoh H. 1984. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases. Trends Pharmacol. Sci. 5:237-39
33. Lindgren SHS, Andersson TLG, Vinge E, Andersson K-E. 1990. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol. Scand. 140:209-19
34. Meisheri KD, Pagani ED, VanAller GS, O'Connor B, Silver PJ. 1993. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur. J. Pharmacol. 243:141-44
35. Kauffman RF, Schenck KW, Utterback BG, Crowe VG, Cohen ML. 1987. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J. Pharmacol. Exp. Ther. 242: 864-72
36. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. 1988. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313-20
37. Rossig TH, Drazen JM. 1986. Effects of milrinone on contractile responses of guinea pig trachea, lung parenchyma and pulmonary artery. J. Pharmacol. Exp. Ther. 238:874-79
38. Wilmshurst PT, Walker JM, Fry CH, Mounsey JP, Twort CHC, et al. 1984. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc. Res. 18:302-9
39. Lindgren S, Andersson K-E, Belfrage P, Degerman E, Manganiello VC. 1989. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol. Toxicol. 64:440-45
40. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J. Pharmacol. Exp. Ther. 247:34-42
41. Maurice DH, Crankshaw D, Haslam RJ. 1991. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur. J. Pharmacol. 192: 235-42
42. Haynes J, Kithas PA, Taylor AE, Strada SJ. 1991. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am. J. Physiol. 261:H487-92
43. Francis SH, Noblett BD, Todd BW, Wells JN, Corbin JD. 1988. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol Pharmacol. 34:506-17
44. Hyman AL, Kadowitz PJ, Lippton HL, 1989. Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J. Appl. Physiol. 66:1513-17
45. 2+ β cAMP in vascular smooth muscle cells. Am. J. Physiol. 258:C399-407
46. Haynes J, Robinson J, Saunders L, Taylor AE, Strada SJ. 1992. Role of cAMP-dependent protein kinase in cAMP-mediated vasodilation. Am. J. Physiol. 262:H511-16
47. Hei Y, MacDonell KL, McNeil JH, Diamond J. 1991. Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs. Mol. Pharmacol. 39:233-38
48. Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet JC. 1987. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. Biochem. Pharmacol. 36:3965-72
49. Beavo JA, Reifsnyder DH. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:150-55
50. Heaslip RJ, Buckley SK, Sickels BD Grimes D. 1991. Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog. J. Pharmacol. Exp. Ther. 257:741-47
51. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S Saito I. 1995. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J. Pharmacol. Exp. Ther. 272: 825-31
52. Murray KJ. 1993. Phosphodiesterase VA inhibitors. Drug News Persp. 6: 150-56
53. Martin W, Furchgott RF, Villani GM, Jothianandan D. 1986. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther. 237:539-47
54. Ignarro LJ, Byrns RE, Wood KS. 1987. Endothelium-dependent modulation of cGMP levels in intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ. Res. 60:82-92
55. Villanueva MM, Nunes JP, Soares-da-Silva P. 1991. Relaxant effects of α-human atrial natriuretic peptide on venous smooth muscle. J. Auton. Pharmacol. 11:139-45
56. Merkel LA, Rivera LM, Perrone MH, Lappe RW. 1992. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur. J. Pharmacol. 216:29-35
57. Wood LM, Owen DAA. 1989. A comparison of vasodilator activity of agents activating cyclic nucleotides with those inhibiting their metabolism in rabbit isolated ear artery. Br. J. Pharmacol. 96: 718-24
58. Silver PJ, Pagani ED, de Garavilla L, VanAller GS, Volberg ML, et al. 1991. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinas. Eur. J Pharmacol. 199:141-42
59. Kukovetz WR, Holzmann S, Wurm A, Poch G. 1979. Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol. 310:129-38
60. Ahlner J, Andersson RGG, Axelsson KL, Bunnfors I, Wallentin L. 1985. Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relationship to cyclic nucleotide metabolism. Arch. Pharmacol. Toxicol. 57:88-95
61. Ahlner J, Andersson RGG, Axelsson KL, Dahlstrom U, Rydell EL. 1986. Development of tolerance to glyceryl trinitrate in an isolated human peripheral vein and its relation to cyclic GMP metabolism. Acta Pharmacol. Toxicol. 59:123-28
62. Bohyn M, Berkenboom G, Fontaine J. 1991. Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein. Cardiovasc. Drugs Ther. 5:457-62
63. Silver PJ, Dundore RL, Bode DC, De Garavilla L, Buchholz A, et al. 1994. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 271:1143-49
64. Kodama K, Adachi H, Mori N, Saito I. 1994. Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs. Eur. J. Pharmacol. 263:93-99
65. Braner DAV, Fineman JR, Chang R, Soifer SJ. 1993. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264:H252-58
66. Trapani AJ, Smits GJ, McGraw DE, McMahon EG, Blaine EH. 1991. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 258:269-74
67. McMahon EG, Palocno MA, Mehta P, Olins GM. 1989. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3′5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 251:1000-5
68. m cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine. J. Cardiovasc. Pharmacol. 16:501-5
69. Dundore RL, Pratt PF, O'Connor B, Buchholz RA, Pagani ED. 1991. N-Nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast. Eur. J. Pharmacol. 200:83-87
70. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. 1990. Syndromes of accelerated atherosclerosis, role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol. 15:1667-87
71. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem. J 288:527-32
72. Garg UC, Hassid A. 1989. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1774-77
73. Kariya K, Kawahara Y, Araki S, Fukuzaki H, Takai Y. 1989. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 80: 143-47
74. Schoeffter P, Lugnier C, Travo C, Stoclet J-C. 1989. A comparison of cyclic AMP signaling system in rat aortic myocytes in primary culture and aorta. Lab. Invest. 61:177-82
75. Souness JE, Hassall GA, Parrott DP. 1992. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44:857-66
76. Xiong Y, Westhead EW, Slakey LL. 1995. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem. J. 305:627-33
77. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Poison JB. 1994. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48:827-35
78. Pan X, Coffey RG, Fitzpatrick DF, Krzanowski JJ, Slater RE. et al. 1992. Effects of vinpocetine and zaprinast on the proliferation of A10 cells. FASEB J. 6:A1846
79. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, et al. 1992. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 20: 900-6
80. Shirotani M, Yui Y, Hattori R, Kawai C. 1991. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 41:97-110
81. Beavo J, Houslay MD, eds. 1990. Cyclic Nucleotide Phosphodiestereases: Structure, Regulation and Drug Action. Chichester, UK: Wiley
82. Torphy TJ, Undem BJ. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-23
83. Nicholson CD, Challiss RAJ, Shahid M. 1991. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12:19-27
84. Thompson WJ. 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmac. Ther. 51:13-33
85. Strada SJ, Hidaka H, eds. 1992. The Biology of Cyclic Nucleotide Phosphodiesterases. Advances in Second Messenger and Phosphoprotein Research. Vol. 25. New York: Raven
86. Bolger GB. 1994. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signal. 6:851-59
87. Sheth SB, Colman RW. 1995. Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design. Semin. Hematol. 32:110-19
88. Conti M, Nemoz G, Sette C, Vicini E. 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16:370-89
89. Pittler SJ, Baehr W. 1991. Identification of a nonsense mutation in the rod pnotoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc. Natl. Acad. Sci. USA 88:8322-26
90. Suber ML, Pittler SJ, Qin N, Wright GC, Holcombe V, et al. 1993. Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phodiesterase beta-subunit gene. Proc. Natl. Acad. Sci USA 90:3968-72